World Allergy Organization Journal is a premier open-access publication dedicated to advancing the understanding and treatment of allergic diseases and related conditions. Published by ELSEVIER, this journal boasts a commendable impact factor and ranks in the second quartile for both Immunology and Allergy, as well as the first quartile in Pulmonary and Respiratory Medicine. Since its inception as an open-access journal in 2008, it has consistently aimed to provide a credible platform for researchers, clinicians, and students to disseminate original research, reviews, and clinical studies. With its emphasis on high-quality scholarship and practical applications, the World Allergy Organization Journal plays a crucial role in bridging theoretical knowledge with clinical practice, making significant contributions to the fields of immunology, allergy, and respiratory medicine. The journal is particularly notable for its accessibility to a global audience, exemplified by its open-access model since 2008, promoting a wider exchange of ideas and innovations across borders.

ALLERGY is a leading international journal published by WILEY, dedicated to advancing the understanding of allergic diseases and immunology. With an ISSN of 0105-4538 and an E-ISSN of 1398-9995, this esteemed journal has been at the forefront of the field since its inception in 1948 and continues to publish high-quality research up until 2024. Positioned in the Q1 category for both Immunology and Allergy, ALLERGY ranks impressively within the top percentiles of its categories, underscoring its significant impact, as reflected in its Scopus rankings (#11 out of 233 in Immunology and Allergy, and #14 out of 236 in Immunology and Microbiology). Researchers and practitioners accessing this journal can expect a rigorous selection of peer-reviewed articles that address current challenges, innovative therapies, and advancements in the immunological sciences. Although it is not an open-access journal, ALLERGY remains vital for academics, healthcare professionals, and students alike, fostering a deeper understanding of the mechanisms and treatments associated with allergies.

The Journal of Allergy and Clinical Immunology-In Practice, published by ELSEVIER, stands as a leading platform in the field of allergy and immunology, specifically tailored for practitioners and researchers. With an impressive 2023 Q1 ranking in both the Immunology and Allergy categories, this journal demonstrates a significant impact within the academic community, evidenced by its Scopus rank #41 out of 233 and an impressive percentile rank of 82. The journal focuses on providing advanced studies, clinical findings, and innovative treatment methodologies that address current challenges in allergy and immunology, making it a vital resource for professionals in these fields. With a comprehensive coverage of relevant topics from 2013 to 2024, the journal continues to evolve alongside emerging trends and developments in clinical practice, fostering an environment conducive to scholarly research and application. Although it currently does not offer open access, authors and readers can access a wealth of information and contribute to ongoing dialogues through its robust publication platform.

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA is a premier journal published by W B SAUNDERS CO-ELSEVIER INC, focusing on the dynamic fields of immunology and allergy. With an ISSN of 0889-8561 and an E-ISSN of 1557-8607, this journal has consistently ranked in the Q2 category in both Immunology and Immunology and Allergy as per 2023 metrics, underscoring its critical role in academia. It provides cutting-edge research, comprehensive reviews, and practical insights that cater to the needs of researchers, clinicians, and students alike. Though the journal is not open access, it remains an essential resource for those involved in advancing knowledge and clinical practice in allergy and immunology. With its converged years stretching from 1987 to 2024, the journal serves as a rich repository of scientific advancements, fostering progress in diagnosis, treatment, and prevention of allergic diseases and immune disorders. Positioned within the United States and based in Philadelphia, it plays a vital role in promoting scholarly communication within these impactful fields.

The Revue Francaise d'Allergologie, an esteemed publication in the field of Immunology and Allergy, is published by ELSEVIER MASSON, CORP OFF in France. This journal plays a pivotal role in disseminating significant findings and advancements in allergy research and immunotherapy, reflecting the latest trends and challenges in these rapidly evolving areas. As part of its commitment to scholarly rigor, the journal encompasses a wide range of topics pertinent to allergology, aiming to bridge the gap between clinical practice and academic research. Although currently not listed as open access, it provides critical insights essential for researchers, professionals, and students alike, ensuring the advancement of knowledge and therapeutic strategies in allergy and immunology. With its impact factor and positioning in the Q4 category, it serves as a valuable resource, aiding in the education and development of future leaders in the field. The Revue Francaise d'Allergologie continues to be a vital platform for the exchange of innovative ideas and findings from 2009 to the present.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY is a premier peer-reviewed journal published by Elsevier Science Inc, dedicated to advancing the fields of allergy, asthma, and immunology. With its roots dating back to 1995 and with a focus on high-impact research, this journal has established itself as a leading platform for the dissemination of original research, reviews, and clinical studies within these critical areas. The journal boasts an impressive impact factor, supporting its Q2 ranking in both Immunology and Allergy, as well as in Pulmonary and Respiratory Medicine, indicating its significant contribution to the scientific community. Although it does not currently offer open access options, its comprehensive coverage and rigorous peer-review process ensure that published articles are of the highest quality, making it an invaluable resource for researchers, clinicians, and students alike. The Scopus rankings reflect its esteemed position in the academic landscape, providing professionals with access to cutting-edge developments and insights into the management and treatment of allergic and respiratory conditions.

Postepy Dermatologii i Alergologii is a distinguished Open Access journal published by TERMEDIA PUBLISHING HOUSE LTD, dedicated to advancing the fields of Dermatology and Immunology and Allergy. Since its inception in 2003, this journal has served as a vital platform for researchers and practitioners alike, promoting knowledge sharing and collaboration in Poland and beyond. With a current impact ranking placing it in the Q3 quartile for both Dermatology and Immunology and Allergy categories, it plays a significant role in contributing to academic discourse within these fields. The journal is indexed in Scopus, with respectable rankings reflecting its relevance and quality—#65/142 in Dermatology and #163/233 in Immunology and Allergy. Researchers are encouraged to explore a vast array of innovative studies and reviews, making it an essential resource for anyone seeking to stay at the forefront of dermatological and allergic research. For those interested in discovering groundbreaking findings and contributing to the ongoing dialogue in these disciplines, Postepy Dermatologii i Alergologii offers not only free accessibility but also a commitment to scholarly excellence.

The ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY, published by the Allergy Immunology Society of Thailand, is a pivotal platform for disseminating high-quality research in the fields of allergy and immunology. Established in 1983, this journal has consistently evolved to address the pressing challenges and advancements in these dynamic disciplines, contributing significantly to the global scientific community's understanding of immunological disorders. With a category ranking of Q3 in Immunology and Allergy, and Q2 in Medicine (miscellaneous) for 2023, the journal stands at the forefront of impactful research, engaging with a diverse audience of researchers, clinicians, and students alike. Although it operates on a non-open access model, its rigorous peer-review process ensures that published articles meet the highest academic standards. Located in Bangkok, Thailand, the journal connects researchers across the Asia-Pacific region, fostering collaboration and innovation to enhance patient care in the realm of allergy and immunology.

Allergy Asthma & Respiratory Disease is a pioneering journal dedicated to advancing research and clinical practice in the fields of allergy, asthma, and related respiratory diseases. Published by the esteemed Korean Academy of Asthma Allergy & Clinical Immunology, this journal aims to disseminate high-quality, peer-reviewed articles that contribute to the understanding, diagnosis, and treatment of these prevalent health issues. Although it operates under a subscription model, it maintains a robust reputation for being a pivotal resource in respiratory health, attracting authors and researchers worldwide. The journal emphasizes interdisciplinary approaches and encourages submissions that span from molecular biology to public health perspectives, making it a vital platform for professionals, researchers, and students eager to deepen their knowledge in respiratory medicine. With a commitment to fostering academic discourse in South Korea and beyond, Allergy Asthma & Respiratory Disease is positioned as a significant contributor to the global conversation on respiratory health.

Current Treatment Options in Allergy is an esteemed academic journal published by SpringerNature, focusing on a critical area of health science: the evolving landscape of allergy treatments. With an E-ISSN of 2196-3053, this journal aims to provide a comprehensive platform for researchers and practitioners in the fields of Immunology and Allergy and Medicine. It has garnered recognition in the academic community, reflecting its significant contribution with a Q3 ranking in Immunology and Allergy and a Q3 ranking in Medicine as of 2023. The journal is based in Switzerland and encompasses research spanning from 2014 to 2024, ensuring that the latest findings and treatment options are available to professionals and students alike. With a growing focus on open access, it aims to make critical allergy treatment research widely accessible, thus fostering innovation and collaboration in this vital health sector. As the prevalence of allergies continues to rise globally, Current Treatment Options in Allergy plays a crucial role in disseminating important research and treatment strategies to improve patient outcomes.